Manufacturing: Page 12
-
Drugmakers boost production of malaria pill touted by Trump as coronavirus treatment
Chloroquine, a decades-old generic therapy, has drawn attention as a potential therapy for COVID-19, although the evidence supporting its promise is thin.
By Ned Pagliarulo • Updated March 20, 2020 -
US automakers study medical manufacturing as coronavirus squeezes capacity
Switching to produce medical equipment will require new supply lines running to manufacturing facilities that are capable of delivering needed components.
By Matt Leonard • March 19, 2020 -
Courtesy of Centers for Disease Control and Prevention
How an 'overwhelmed' Buffalo lab facing coronavirus supply shortage signals nationwide struggles
Labs like the one in western New York face insufficient stocks of swabs and reagents as they attempt to gauge the outbreak's spread.
By Greg Slabodkin • March 18, 2020 -
Regeneron expects its antibody cocktail for coronavirus to enter human testing in early summer
The biotech is prepping manufacturing facilities so that, once the top antibody contenders are selected, clinical production can quickly begin. By the end of the summer, the aim is to make hundreds of thousands of doses per month.
By Jacob Bell • March 17, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
Vir, signaling its commitment, taps Biogen to make coronavirus treatment
For smaller biotechs like Vir, manufacturing is a likely roadblock to advancing any promising drug candidate that might emerge from initial testing.
By Kristin Jensen • March 12, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Coronavirus spread prompts FDA to postpone nearly all overseas inspections
The agency's decision was based on U.S. government travel restrictions, but it said "alternative tools and methods" will help it maintain oversight.
By Jonathan Gardner • March 10, 2020 -
Hospitals dipping into emergency stocks to combat coronavirus
Community spread of COVID-19 has hospitals bracing for a rush of patients and payers waiving fees for telemedicine consults and extra drug supplies.
By Shannon Muchmore • March 10, 2020 -
After waffling, Qiagen agrees to $11.5B buyout by Thermo Fisher
The instruments maker will pay a 23% premium to take out Qiagen, adding to the diagnostics side of its business after investments in its contract drug offerings.
By Maria Rachal • March 3, 2020 -
FDA reports first drug shortage due to coronavirus impact
Supplies of the drug, which the FDA did not identify, ran short as a result of issues at a site that produces the active ingredient. Other options are available, the agency said.
By Ned Pagliarulo • Updated March 2, 2020 -
As shortages draw spotlight, Sanofi to spin out drug ingredient business
The new company will launch with significant size, employing 3,100 and drawing from a network of six factories across Europe.
By Ned Pagliarulo • Feb. 24, 2020 -
With supply tight, Novartis readies gene therapy plant for production
Bringing the facility in Durham, North Carolina, online is a critical step for the Swiss pharma's plans to expand the market for Zolgensma, its gene therapy for spinal muscular atrophy.
By Ned Pagliarulo • Feb. 21, 2020 -
WuXi Vaccines inks $3B manufacturing deal with 'global vaccine leader'
Set to last 20 years, the contract between Wuxi and an unidentified vaccine maker calls for the Chinese CDMO to build a dedicated production plant.
By Kristin Jensen • Updated Feb. 21, 2020 -
Audentes to spend $110M on new gene therapy plant in North Carolina
The biotech, which was bought last year by Astellas, joins Pfizer, Bluebird bio and AveXis in choosing to locate gene therapy manufacturing in the state.
By Ned Pagliarulo • Feb. 18, 2020 -
Jacob Bell/BioPharma Dive
FDA monitoring impact of coronavirus outbreak on medical product supply
The agency postponed drug and device inspections in China that were scheduled for February, limiting its oversight of a key country in the medical supply chain.
By Nick Paul Taylor • Feb. 18, 2020 -
In turnaround bid, Teva tries to wring more savings out of manufacturing
The generic maker's push to reduce manufacturing costs follows a restructuring that's saved $3 billion but resulted in layoffs for thousands of employees.
By Kristin Jensen • Feb. 13, 2020 -
Lonza resuming production as coronavirus spread threatens manufacturers
The Swiss contractor briefly extended holiday plant closures in China in response to the outbreak, which has also disrupted Airbus and Hyundai.
By Kristin Jensen • Feb. 6, 2020 -
Catalent, expecting a boom in cell therapy, bids for Masthercell
With biologics driving growth, the contract manufacturer is looking to diversify with a $315 million purchase that hands it a slate of production sites.
By Jacob Bell • Feb. 3, 2020 -
Amgen, Pfizer biosimilar sales pressure top drugs
Competition is heating up for copycats to Roche's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting.
By Jonathan Gardner • Jan. 31, 2020 -
German Merck continues manufacturing buildout with $275M investment
The money will go toward a 15,700-square-meter facility, to be called the Biotech Development Center, that's set to be fully operational by 2022.
By Jacob Bell • Jan. 30, 2020 -
AstraZeneca pledges to go 'carbon negative' by 2030
Matching a recent commitment from Microsoft, AstraZeneca says it's stepping up its climate efforts. Recent numbers show the pharma has a ways to go.
By Ned Pagliarulo • Jan. 23, 2020 -
Blue Cross Blue Shield partners with Civica on generic drug mission
The Blue Cross Blue Shield Association, along with 18 affiliate companies, will invest $55 million to create a new unit of the generic drug company.
By Kristin Jensen • Jan. 23, 2020 -
Courtesy of Eli Lilly
Lilly to invest $470M in new North Carolina drug plant
The facility, which will employ more than 400, is part of a broader build-out by Lilly of its manufacturing network.
By Kristin Jensen • Jan. 22, 2020 -
Civica advances drug supply strategy with Thermo Fisher deal
The seven-year partnership will initially focus on nine critical medicines vulnerable to supply chain interruptions.
By Jonathan Gardner • Jan. 16, 2020 -
Nationwide Children's, a gene therapy leader, launches manufacturing spinout
Andelyn Biosciences, named after two children treated with gene therapy at Nationwide, will operate as a for-profit subsidiary of the Ohio-based hospital.
By Ned Pagliarulo • Updated Jan. 15, 2020 -
Courtesy of Eli Lilly
Lilly, Strateos open remote-controlled robotic research lab in San Diego
The lab, which is part of a $90 million investment Lilly made in its San Diego site two years ago, will be accessible to emerging drug discovery companies.
By Kristin Jensen • Jan. 9, 2020
Previous
